dm+d

Unassigned

New Medicines

Dominantly inherited Alzheimer's disease (DIAD)

Information

New molecular entity
Eisai
Eisai

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

An anti-tau monoclonal antibody. Tau protein is one of the pathological features of AD, that is believed to spread throughout the brain through synaptically-connected pathways. E 2814 is designed to target microtubule binding region of tau (MTBR) containing tau species, preventing build-up and spreading of tau seeds, thereby slowing the course of the disease.
Dominantly inherited AD (DIAD) is a rare form of AD that causes memory loss and dementia in individuals — typically while they are in their 30s to 50s. The disease affects less than 1% of the total population of people with AD [1].
Dominantly inherited Alzheimer's disease (DIAD)
Intravenous